Physician profile
Chona Ray
NPI 1932128402
$1,626.70
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,531 · 2022: $77.45 · 2023: $17.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $17.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $17.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.11 | 2021 | |
| Celgene Corporation | $118.09 | 2021 | |
| Seagen INC. | $109.18 | 2021 | |
| Lilly USA, LLC | $107.87 | 2021 | |
| Amgen INC. | $106.44 | 2021 | |
| Incyte Corporation | $91.20 | 2021 | |
| Genentech USA, INC. | $89.47 | 2021 | |
| Pfizer INC. | $82.64 | 2021-2023 | |
| Daiichi Sankyo INC. | $72.21 | 2021 | |
| Kite Pharma, INC. | $67.52 | 2021 | |
| Astellas Pharma US INC | $62.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $58.91 | 2021 | |
| Exelixis INC. | $55.79 | 2021 | |
| Karyopharm Therapeutics INC. | $52.35 | 2021 | |
| Coherus Oncology, INC. | $44.71 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.65 | 2021-2022 | |
| Adc Therapeutics America, INC. | $36.30 | 2022 | |
| Merck Sharp & Dohme LLC | $35.87 | 2021 | |
| Janssen Biotech, INC. | $34.64 | 2021 | |
| Puma Biotechnology, INC. | $29.18 | 2021 | |
| Glaxosmithkline, LLC. | $25.62 | 2021 | |
| Eisai INC. | $23.64 | 2021 | |
| Blueprint Medicines Corporation | $23.18 | 2021 | |
| Emmaus Medical, INC. | $22.10 | 2021 | |
| Genzyme Corporation | $19.38 | 2021 | |
| Morphosys, US INC. | $18.16 | 2021 | |
| Abbvie INC. | $18.14 | 2021 | |
| Dova Pharmaceuticals | $16.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chona Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.